Media Centre

Featured Media Release

10 Nov 2011 - New PBS listing of REVOLADE® (eltrombopag olamine) tablets increases access to treatment options for Australians withchronic ITP

As of 1 November 2011, Australians with the rare blood disorder, chronic immune (idiopathic) thrombocytopenic purpura (ITP), will have increased access to treatment options for chronic ITP with the listing of REVOLADE® (eltrombopag) tablets on the Pharmaceutical Benefits Scheme (PBS).1,2


Media Releases

New medicine for lupus now available in Australia

GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite...



Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease...



Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in...




Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner



$80,000 to local communities to boost immunisation

GSK’s 2014 Immunisation Grants for local communities were launched today at the Public Health Association of Australia’s 14th annual immunisation conference. The grants aim to help improve access, coverage and timely delivery of vaccination services.



GSK Response to CHOICE Media Release

GSK would like to respond to some of the allegations made in the CHOICE media release – Pain Pills Hurting The Hip Pocket.



GSK Australia Reports 2013 results to ASIC

GSK Australia reported to the Australian Securities and Investment Commission (ASIC) for 2013, sales of $1,414m and a total profit before tax of $42m.



Skin Science Facility to Close in Rowville, Victoria

GSK announced today the immediate closure of the Stiefel, skin science facility in Rowville, Victoria.



2013 Corporate Responsibility Report Published

GSK Australia and New Zealand today published the second annual corporate responsibility report, outlining key achievements in health, community and environmental sustainability during 2013.



GSK comment: China investigation

“We have today met with the MPS who updated us on their investigation into GSK China Ltd."


1 2 3 4 5 6 7 8 9 10 11 >